Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer Immunol Immunother. 2016 Sep 30;65(12):1523–1532. doi: 10.1007/s00262-016-1904-8

Figure 1. Progression-free survival: tumor PDL-1 expression and KIR-ligand genotypes.

Figure 1

The interaction analysis between tumor PDL1 phenotype and KIR2DL1 (interaction p=0.041) or 3DL1-ligand genotype (interaction p=0.054) was evaluated by Cox proportional hazards analyses with further subgroup comparisons shown below. a) While PDL1+ patients had prolonged PFS than PDL1− patients if they were KIR2DL1-ligand present genotype (p=0.009), there was no difference between PDL1+ and PDL1− patients if they were KIR2DL1-ligand missing. In addition, individuals that were PDL1+ and KIR2DL1-ligand present showed prolonged PFS than patients that are PDL1+ and KIR2DL1-ligand missing (p=0.03); b) While PDL1+ patients had prolonged PFS than PDL1− patients if they were KIR3DL1-ligand present genotype (p=0.007), there was no difference between PDL1+ and PDL1− patients if they were KIR3DL1-ligand missing. In addition, individuals that were PDL1+ and KIR3DL1-ligand present showed a trend towards prolonged PFS than patients that are PDL1+ and KIR3DL1-ligand missing (p=0.057). c) Since the interaction p value between PDL1 and KIR2DL2/3-ligand missing is above 0.1 (interaction p=0.64), the impact from PDL1 expression and KIR2DL2/3-ligand genotypes on PFS are independent from each other. Therefore, no pairwise comparisons were made between the subgroups of patients.